Swedish Orphan Biovitrum AB (publ)

BATS-CHIXE:SOBIS Stock Report

Market Cap: SEK 102.1b

Swedish Orphan Biovitrum Valuation

Is SOBIS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SOBIS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 1.12k
Fair Value
73.3% undervalued intrinsic discount
12
Number of Analysts

Below Fair Value: SOBIS (SEK299) is trading below our estimate of fair value (SEK1121.2)

Significantly Below Fair Value: SOBIS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SOBIS?

Key metric: As SOBIS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SOBIS. This is calculated by dividing SOBIS's market cap by their current earnings.
What is SOBIS's PE Ratio?
PE Ratio25.8x
EarningsSEK 3.96b
Market CapSEK 102.08b

Price to Earnings Ratio vs Peers

How does SOBIS's PE Ratio compare to its peers?

The above table shows the PE ratio for SOBIS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average27.2x
BVXP Bioventix
18.4xn/aUK£143.7m
PRTC PureTech Health
7.4x-90.4%UK£302.6m
HIK Hikma Pharmaceuticals
16.5x11.6%UK£4.4b
HCM HUTCHMED (China)
66.4x16.0%UK£1.9b
SOBIS Swedish Orphan Biovitrum
25.8x16.7%SEK 102.1b

Price-To-Earnings vs Peers: SOBIS is good value based on its Price-To-Earnings Ratio (25.8x) compared to the peer average (27.5x).

Price to Earnings Ratio vs Industry

How does SOBIS's PE Ratio compare vs other companies in the European Biotechs Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies6PE020406080100+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SOBIS is good value based on its Price-To-Earnings Ratio (25.8x) compared to the European Biotechs industry average (27.4x).

Price to Earnings Ratio vs Fair Ratio

What is SOBIS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SOBIS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SOBIS's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SOBIS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 297.60
SEK 354.08
+19.0%
8.5%SEK 383.00SEK 285.00n/a12
May ’26SEK 299.80
SEK 354.42
+18.2%
8.6%SEK 385.00SEK 285.00n/a12
Apr ’26SEK 285.00
SEK 366.33
+28.5%
9.2%SEK 400.00SEK 285.00n/a12
Mar ’26n/a
SEK 368.42
0%
9.5%SEK 405.00SEK 285.00n/a12
Feb ’26n/a
SEK 366.08
0%
10.7%SEK 415.00SEK 275.00n/a12
Jan ’26n/a
SEK 359.73
0%
10.6%SEK 400.00SEK 275.00n/a11
Dec ’25n/a
SEK 360.64
0%
10.9%SEK 410.00SEK 275.00n/a11
Nov ’25SEK 344.80
SEK 351.27
+1.9%
11.2%SEK 410.00SEK 275.00n/a11
Oct ’25SEK 309.80
SEK 325.55
+5.1%
8.9%SEK 370.00SEK 250.00n/a11
Sep ’25SEK 316.60
SEK 328.00
+3.6%
8.5%SEK 370.00SEK 250.00n/a11
Aug ’25SEK 279.30
SEK 328.30
+17.5%
8.9%SEK 370.00SEK 250.00n/a10
Jul ’25n/a
SEK 329.60
0%
6.2%SEK 370.00SEK 285.00n/a10
Jun ’25n/a
SEK 320.00
0%
9.4%SEK 370.00SEK 252.00n/a10
May ’25n/a
SEK 317.22
0%
9.8%SEK 370.00SEK 252.00SEK 299.809
Apr ’25SEK 264.90
SEK 317.70
+19.9%
9.6%SEK 370.00SEK 252.00SEK 285.0010
Mar ’25SEK 256.90
SEK 317.91
+23.7%
9.2%SEK 370.00SEK 252.00n/a11
Feb ’25n/a
SEK 316.20
0%
8.0%SEK 345.00SEK 252.00n/a10
Jan ’25SEK 267.30
SEK 297.00
+11.1%
6.0%SEK 325.00SEK 252.00n/a10
Dec ’24SEK 250.60
SEK 293.00
+16.9%
7.0%SEK 325.00SEK 252.00n/a10
Nov ’24n/a
SEK 287.45
0%
10.0%SEK 325.00SEK 222.00SEK 344.8011
Oct ’24SEK 219.00
SEK 285.55
+30.4%
10.0%SEK 325.00SEK 222.00SEK 309.8011
Sep ’24n/a
SEK 284.18
0%
10.1%SEK 325.00SEK 222.00SEK 316.6011
Aug ’24n/a
SEK 288.27
0%
9.8%SEK 325.00SEK 222.00SEK 279.3011
Jul ’24SEK 209.40
SEK 286.80
+37.0%
10.4%SEK 325.00SEK 216.00n/a10
Jun ’24SEK 212.40
SEK 285.80
+34.6%
10.6%SEK 325.00SEK 216.00n/a10
May ’24SEK 245.00
SEK 287.20
+17.2%
11.5%SEK 325.00SEK 211.00n/a10
AnalystConsensusTarget
Consensus Narrative from 12 Analysts
SEK 356.23
Fair Value
16.1% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/08 15:12
End of Day Share Price 2025/05/06 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Swedish Orphan Biovitrum AB (publ) is covered by 30 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Xue ChenBarclays
Rosie TurnerBarclays